Phase 2a Study for PK/PD of nC-001

nephCentric

Status and phase: Not yet enrolling; Phase 2

Conditions: CHRONIC HYPONATREMIA

Treatments: Drug: nC-001; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06798675

PNC-101

Details and patient eligibility

About

CHRONIC EUVOLEMIC HYPONATREMIA

Enrollment: 24 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Men or women ≥18 and ≤85 years of age
2. Diagnosis of chronic euvolemic hyponatremia

Exclusion criteria

• 1. Hyponatremia assessed by the Investigator to be hypervolemic, hypovolemic, or due to psychogenic polydipsia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

24 participants in 3 patient groups, including a placebo group

15gm

Active Comparator group

Treatment:

Drug: nC-001

30gm

Active Comparator group

Treatment:

Drug: nC-001

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo